- WuXi Biologics (2269.HK) recognized by CDP for climate change leadership for the second consecutive year, achieving an 'A-' score among 25,000 companies.
- Committed to net-zero emissions by 2050, WuXi Biologics achieved a 30% reduction in GHG emission intensity from 2020 levels in 2024.
- Implementing sustainability initiatives, WuXi Biologics has achieved 100% renewable electricity at its Ireland facility.
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has been recognized by CDP for its leadership in climate change for the second consecutive year, receiving an 'A-' score. The recognition was announced on Earth Day 2025, highlighting WuXi Biologics' commitment to transparency and excellence in environmental stewardship.
The company is committed to achieving net-zero emissions by 2050. As of 2024, WuXi Biologics has realized a 30% reduction in greenhouse gas (GHG) emission intensity from 2020 levels. Key sustainability initiatives include the deployment of rooftop photovoltaic power projects and the achievement of a 100% renewable electricity supply at its Ireland facility.
WuXi Biologics has garnered multiple sustainability accolades, including an MSCI AAA Rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices. The company also participates in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, solidifying its commitment to promoting sustainable and environmentally friendly practices throughout its value chain.
Dr. Chris Chen, CEO of WuXi Biologics, emphasized the company's dedication to sustainability and its role as a global leader in Green CRDMO. He noted the importance of the company's efforts in delivering end-to-end solutions that fulfill ESG commitments and promote responsible practices in collaboration with all stakeholders.
